Articles from Paige

Paige, a leader in next-generation AI technology, announced today that its FullFocus™ digital pathology image viewer received FDA 510(k) clearance, for use with the Leica Aperio GT 450 DX scanner (supporting SVS and DICOM file formats) and the Hamamatsu NanoZoomer S360MD Slide scanner system (supporting NDPI file format), with a wide set of monitors1.

Paige, a leader in next-generation AI technology, today announced the company’s foundation models are being showcased by Microsoft at the Las Vegas HLTH 2024 conference as transformative AI technology for healthcare. During a live seminar on October 21st, Matt Lungren, MD and Microsoft Health & Life Sciences’ Chief Scientific Officer, will discuss how AI foundation models are enabling a transformative wave across healthcare.

Paige, a leader in next-generation AI technology unveils Paige Alba™, a clinical-grade multimodal co-pilot designed to revolutionize personalized medicine and precision oncology. Using the power of Paige’s Foundation Models, Alba delivers AI-driven patient insights in real-time and marks a significant step toward Artificial General Intelligence (AGI).

Paige, a leader in next-generation AI technology, announces the launch of OmniScreen, a pioneering AI-driven biomarker module capable of evaluating over 505 genes and detecting 1,228 molecular biomarkers from routine H&E-stained digital pathology slides. Built on Paige’s second-generation foundation model, trained on an unprecedented three million slides, this breakthrough represents a major leap forward in the accuracy, speed, and cost-effectiveness of cancer diagnosis and treatment selection.

Paige, a leader in next-generation AI technology, today announced a strategic shift to further advance the role and impact of AI in cancer care. This initiative includes leveraging its AI technology to bring Artificial General Intelligence (AGI) to pathology and oncology, as well as transitioning its diagnostic AI applications from being exclusive to the Paige Platform to a standalone solution compatible with other digital pathology platforms.

Paige, a global leader in clinical AI applications for cancer, in collaboration with Microsoft, has unveiled the second generation of Virchow, its million-slide foundation model for cancer. As additions to Paige’s suite of foundation models, the world’s largest and most advanced AI models in clinical pathology, Virchow2 and Virchow2G offer a deeper understanding of cells and tissue, aiming to redefine cancer diagnosis and treatment.

Paige, a pioneer in AI-driven pathology solutions designed to improve the fight against cancer, today announced the open-source release of Paige’s Foundation Models, Open Paige Foundation Model (“OpenPFM”), including Virchow and PRISM, two pioneering foundation models for computational pathology, as well as an ML SDK to support the use of these models in the research community. Virchow is the first million-slide foundation model for cancer, while PRISM built on Virchow, is a vision and language model for slide-level cancer insights. These models are now available on Hugging Face, enabling AI developers, academic researchers, and innovators to create customized AI models and applications that accelerate cancer research and clinical development.

Paige, the pioneer in AI-driven pathology solutions designed to improve the fight against cancer, in collaboration with Microsoft, has achieved an important milestone with the publication of a significant study in Nature Medicine. The study highlights the capabilities of Virchow, the first million-slide foundation model for cancer.

In a collaborative project led by the University of Oxford, Paige, a global leader in clinical AI applications that assist in diagnosing cancer, today announced that the Articulate Pro study has achieved live, multisite clinical use study involving three hospital systems across England: North Bristol Trust Southmead Hospital, University Hospitals Coventry and Warwickshire, and Oxford University NHS Foundation Trust. Each hospital uses different digital pathology scanners and information systems and serves distinct patient populations —but are all adding Paige’s powerful artificial intelligence (AI) technology to their standard of care to determine the potential to improve patient outcomes against a background of rising instances of prostate cancer.

Paige, a global leader in end-to-end digital pathology solutions and artificial intelligence (AI) applications, today announced the launch of a new service line based on Paige’s Foundation Models, including the world's largest multi-modal AI model in pathology and oncology. AI developers, organizations building computational pathology products, and life sciences companies will be able to license and use these Foundation Models to develop their own AI models for any research and development, clinical trials, experimental studies, or commercial needs while conforming to the highest set of privacy, security and clinical standards. The result could be a dramatic acceleration of innovation in precision oncology, improving the way cancer is diagnosed and treated around the world.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced the release of a groundbreaking product developed from Paige’s Pathology Foundation Model, Virchow. Built using one of the largest libraries of digitized images, utilizing unique computational resources provided by Microsoft Research, Paige has developed the first application that can detect cancer across more than 17 different tissue types including skin, lung, and the gastrointestinal tract, along with multiple rare tumor types and metastatic deposits.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, today announced a significant expansion of its AppLab™ marketplace, with the addition of six new digital pathology and AI providers. New applications from these industry-leading companies, including Imagene, Histofy, Aiosyn, Clinsight, DoMore Diagnostics, and Stratipath*, will be added to the AppLab to provide support for pathology labs worldwide in building deeply integrated and customized AI-enabled workflows.

At the Radiological Society of North America's (RSNA) 109th Scientific Assembly and Annual Meeting, Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, announced it has teamed up with Nuance, a Microsoft company, to create the largest digital consultation network in pathology. This secure best-in-class platform will revolutionize collaboration among U.S. pathologists, making consultations faster and more efficient. The platform leverages the scale and capabilities of Nuance’s PowerShare image sharing network together with Paige’s track record and expertise in digital pathology and its leading FDA approved viewer.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, announced today that the U.S Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Paige Lymph Node1, an AI application used to detect breast cancer metastases in lymph node tissue. Paige Lymph Node is the first AI application of its kind to receive Breakthrough Device Designation from the FDA.

Paige, a technology disruptor in healthcare, has joined forces with Microsoft in the fight against cancer, making headway in their collaboration to transform cancer diagnosis and patient care by building the world’s largest image-based artificial intelligence (AI) models for digital pathology and oncology.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, today announced a collaboration with Ohio State University Wexner Medical Center (OSWMC) and its affiliated community hospitals. They will conduct a multi-arm clinical utility and health economics study to measure the accuracy, efficiency and cost-savings impact of using AI tools in diagnosing cancer in a community hospital setting. OSWMC will utilize the Paige Prostate Suite, including Paige Prostate Detect, the only FDA approved AI-powered pathology algorithm, to assess the differences between diagnoses made with and without the use of AI.

Paige, a global leader in end-to-end digital pathology solutions and clinical artificial intelligence (AI) applications for diagnosing cancer, and University of Florida College of Medicine – Jacksonville today announced the Department of Pathology and Laboratory Medicine’s decision to adopt Paige’s full portfolio of AI offerings for their lab, including the Paige Prostate Suite and Paige Breast Suite. Powered by the Paige Platform, which offers advanced whole-slide image viewing, seamless integration of Paige and third-party AI, and deep collaboration with industry-leading scanner and LIS vendors, these AI applications support pathologists in the difficult decisions they make every day, offering them greater clinical confidence and supporting them in delivering precision cancer diagnosis.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, today launched the enhanced Paige Breast Suite, a complete set of products designed to empower pathologists in their diagnosis of breast cancer, reduce the subjectivity and tedium of manual diagnosis, and increase diagnostic efficiency and confidence. The Paige Breast Suite includes Paige Breast Detect, Paige Breast Neoplasm, Paige Breast Mitosis, Paige Breast Lymph Node and HER2Complete, a comprehensive group of AI tools that help to support every step of breast cancer diagnosis and to streamline pathologists’ day-to-day workflows.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, today announced a new AI-based digital assay to support pathologists in the detection and diagnosis of microsatellite instability (MSI) status in colon cancers. Paige Colon MSI operates on whole slide images of hematoxylin and eosin (H&E)-stained slides alone, offering slide-level classification of MSI status in colon cancer samples* based on morphologies associated with the presence or absence of MSI/MMR phenotype. Paige Colon MSI is a new addition to Paige’s Colon Suite which also includes case and slide-level detection of suspicious regions including invasive carcinoma and high-grade dysplasia.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, today introduced new advanced integration capabilities to the Paige Platform, a holistic web-based solution that enables complete digital pathology workflows and supports the evolving needs of today’s modern lab.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications to assist in diagnosing cancer, today announced it is working with Visiopharm, an artificial intelligence (AI)-driven precision pathology software provider, to bring a wider range of AI products to doctors and patients. Visiopharm’s AI applications will be deployed and natively integrated into the Paige Platform to be accessed through FullFolio™, Paige’s AI-powered clinical worklist, and viewed within FullFocus®, Paige’s whole-slide image viewer. This deep integration offers users greater diagnostic efficiency and quality insights when reviewing IHC-stained slides and creates a seamless user experience for Visiopharm’s image analysis applications, to help pathologists deliver faster, more accurate and more reproducible cancer diagnoses.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, and Leica Biosystems, a cancer diagnostics company and global leader in workflow solutions, today announced an expanded partnership to enhance the use of digital pathology workflows at hospitals and laboratories around the world. Building upon its existing partnership, Leica Biosystems has selected Paige as the preferred provider of software-as-a-service (SaaS) digital pathology image management and viewing software along with diverse embedded AI solutions for their line of Aperio GT 450 digital pathology slide scanners.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced the availability of Mindpeak’s AI algorithms for IHC biomarker quantification in the Paige Platform. Mindpeak, a leader in image analysis AI software, brings state-of-the-art AI algorithms for analyzing IHC slides of lung and breast tissue into the Paige Platform. These two leading pathology AI providers have combined their technologies to help pathologists deliver faster, more accurate, and more reproducible quantitative cancer diagnoses, even in the most challenging and complex cases.

Paige announced a collaboration with Microsoft to apply the power of artificial intelligence (AI) to digital pathology images to develop and deliver a new generation of clinical applications and computational biomarkers to transform cancer diagnosis and patient care. Microsoft will also make a strategic investment in Paige to accelerate the development and deployment of life-saving AI diagnostics.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced it has published the results of a pivotal study demonstrating accuracy gains in pathologists’ diagnosis of prostate cancer when using Paige Prostate Detect, an FDA-authorized AI software that assists pathologists in the detection of foci that are suspicious for cancer during the review of scanned whole slide images (WSI) from prostate needle biopsies. The results were published in the Archives of Pathology & Laboratory Medicine and are available online here.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced it has entered into a multi-stage research agreement with the University Medical Center (UMC) Utrecht in the Netherlands. UMC Utrecht will deploy Paige AI applications for routine clinical use and conduct a clinical health economics study to support the adoption and reimbursement of AI applications in pathology.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, and OptraSCAN®, a leading producer of whole slide scanners, today announced a partnership to streamline the adoption of digital pathology technology in the United States, European Union countries and United Kingdom. The companies aim to reduce barriers to digitizing glass pathology slides, which will in turn enhance workflows in pathology and oncology.

Paige, a global leader in clinical AI applications for pathology, today announced it will partner with Sonora Quest Laboratories, the local market leader in clinical diagnostics in the state of Arizona, to implement a fully digital pathology workflow at its laboratories. The goal of the digital transformation project is to improve existing diagnostic workflows and accelerate precision diagnoses for patients across Arizona.

Paige, a global leader in clinical AI applications in pathology, today announced it received CE-IVD and UKCA marks for HER2Complete, an artificial intelligence (AI) software designed to identify patients with breast cancer whose tumors have expressions of human epidermal growth factor receptor 2 (HER2) protein.* This is the first CE-IVD and UKCA designated tool to explore the novel space of HER2-low. In a recent study, HER2Complete was able to detect levels of HER2 expression in HER2-negative (IHC-0) and HER2-low (IHC1+/2+) hematoxylin and eosin (H&E)-stained tissue samples, the first and only AI biomarker assay capable of doing so.

Paige, a global leader in clinical AI applications in pathology, today announced a collaboration with Janssen Research & Development, LLC (Janssen) to evaluate the potential of a hematoxylin and eosin (H&E)-based, artificial intelligence (AI)-powered biomarker test to predict the presence of certain actionable alterations in the fibroblast growth factor receptor (FGFR) genes in patients with advanced urothelial cancer, also known as bladder cancer.

Paige, a global leader in clinical AI applications in pathology, today announced it received CE-IVD and UKCA marks for the Paige Prostate Biomarker Suite, an AI software that is designed to detect the presence of four prostate cancer biomarkers on digitized tissue images stained with hematoxylin and eosin (H&E)*. This is the first European regulatory certification of image-based biomarker detection on H&E-stained tissue samples for Paige, potentially expanding the utility of AI to analyze tissues prepared with the most frequently used stain in histology.

Paige, a global leader in AI applications in pathology, today announced several additions to its Scientific Advisory Board as it enters its next phase of growth across its clinical and life sciences businesses. The new advisors include leaders in pathology, oncology, machine learning and the biopharmaceutical industry.

Paige, a global leader in clinical AI applications in pathology, today announced it received CE-IVD and UKCA marks for Paige Breast Lymph Node. The newly launched AI medical device software helps pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review. With the CE-IVD and UKCA designations, laboratories and hospitals in the European Economic Area, Switzerland and the UK can now use the product in the course of clinical diagnosis.*

Paige, the global leader in AI-based diagnostic software in pathology, today launched its latest product, Paige Breast Lymph Node, an AI medical device software that helps pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review*. The product was unveiled at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place March 19-24, 2022.

Paige, the global leader in AI-based diagnostic software in pathology, today announced it will participate in the United States and Canadian Academy of Pathology (USCAP) 2022 Annual Meeting, taking place virtually and in-person at the Los Angeles Convention Center in Los Angeles from March 19-24, 2022. David Klimstra, M.D., Founder and Chief Medical Officer, will join Juan Retamero, M.D., Medical Director, in hosting a seminar on clinical AI applications in pathology and their role in improving patient safety. Paige will also provide an overview and hands-on demonstration of its products, including FDA-approved Paige Prostate Detect, at booth #816 from March 21-23, 2022.

Paige, the global leader in AI-based diagnostic software in pathology, and Flagship Biosciences, a leader in data-centric pathology and tissue analysis, today announced a partnership to provide access to Flagship’s TissueInsight™, an AI-aided diagnostics software that quantifies PD-L1 expression in immunohistochemistry tissue samples, directly through the Paige Platform.

Paige, the global leader in AI-based diagnostic software in pathology, and Mindpeak, the European leader for AI-based software for image analysis in pathology, today announced a distribution partnership, which will enable pathologists to use Mindpeak’s BreastIHC* within the Paige Platform. Mindpeak’s BreastIHC is an AI software that reliably and accurately detects, classifies and quantifies breast cancer cells. This partnership enhances the utility of the Paige Platform by providing real-time results for routine breast cancer immunohistochemistry (IHC) biomarkers.

Paige, the global leader in AI-based diagnostic software in pathology, today announced that it has appointed Andy Moye, Ph.D., as Chief Executive Officer and Jill Stefanelli, Ph.D., as President and Chief Business Officer.

Paige, the global leader in AI-based diagnostic software in pathology, today announced that University of Louisville (UofL) Health, a leading academic health system based in Louisville, Kentucky, has deployed a full suite of Paige AI-enabled digital pathology software to improve diagnostic confidence, efficiency, and patient care during routine cancer diagnosis.

Paige, the global leader in AI-based diagnostic software in pathology, today announced it will present new data demonstrating the performance of Paige Breast “Beta” in detecting various forms of breast cancer and highlight the accuracy of a new AI-based system that detects invasive lobular carcinoma (ILC), the most frequent subtype of breast cancer. The data will be featured during a Spotlight Poster Discussion at the upcoming 2021 San Antonio Breast Cancer Symposium (SABCS 2021), taking place virtually and in-person at the Henry B. Gonzalez Convention Center in San Antonio, Texas from December 7-10, 2021.

Paige, the global leader in AI-based diagnostic software in pathology, today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) published a Medtech Innovation Briefing (MIB) on Paige Prostate, a clinical-grade artificial intelligence (AI)-based diagnostic software system that aids pathologists in detecting, grading and measuring prostate tumors in biopsies obtained from patients at risk of prostate cancer.* This marks the first-ever MIB for a digital pathology product.

Paige, the global leader in AI-based diagnostic software in pathology, today announced a series of presentations at the Pathology Visions 2021 conference, taking place in-person at the MGM Grand in Las Vegas, Nev. from October 17-19, 2021, and hosted by the Digital Pathology Association.

Paige, the global leader in AI-based diagnostic software in pathology, today announced that the U.S. Food and Drug Administration (FDA) has granted de novo marketing authorization for Paige Prostate, a clinical-grade AI solution for prostate cancer detection. As a novel technology, Paige Prostate is the first AI-based pathology product to receive de novo approval from the FDA, allowing in vitro diagnostic (IVD) use via Paige’s FDA-cleared FullFocus™ digital pathology viewer.

Perspectum and Paige today announced a strategic business partnership to leverage quantitative and artificial intelligence (AI) based tools to empower pathologists and enhance decision-making in clinical trials. Perspectum and Paige will join forces to improve the current pathology workflow for large studies through the integration of Paige’s digital pathology platform.

Paige, a global leader in AI-based diagnostic software in pathology, today announced that the Company, Oxford University and National Health Service (NHS) regional partners in the United Kingdom have won the prestigious Phase 4 Artificial Intelligence in Health and Care award from the NHS Accelerated Access Collaborative to study Paige Prostate prospectively in a real-world cancer laboratory setting.

Paige, the global leader in AI-based diagnostic software in pathology, today announced that leading pathologist and Paige co-founder David Klimstra, M.D. has joined as Chief Medical Officer effective August 2021. Dr. Klimstra is an internationally recognized leader in cancer pathology whose career spans more than three decades. In this new role, Dr. Klimstra will lead the clinical implementation and evidence generation for Paige’s technology and will shape product strategy for the most compelling use cases, helping pathologists realize the benefits of the enhanced clinical workflows enabled by Paige's technology.

Paige, a global leader in AI-based cancer diagnostic software tools for digital pathology, and Grupo Oncoclinicas (“Oncoclinicas”), the largest private provider of cancer care in Latin America, today announced the publication of a peer-reviewed study in the Journal of Pathology that shows Paige Prostate, a clinical-grade AI solution for prostate cancer detection*, demonstrated improvements to pathologists’ workflow in a real-world environment.

Paige, a global leader in AI-based digital diagnostics, and Leica Biosystems, a globally recognized cancer diagnostics and workflow solution leader, today announced a strategic partnership to expand access to computational pathology products for clinical and translational research. The partnership brings Paige’s AI-enabled research software for tumor detection, grading and quantification to Leica Biosystems digital pathology platform in select countries throughout North America and Europe.